Cargando…

Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia

Schizophrenia has a multidomain symptom cluster, including positive, negative, and cognitive symptoms. Synthetic cannabinoids (SC) commonly perpetuate the positive symptoms of schizophrenia. We present a case of predominant negative symptoms following the use of SC even though our patient had a cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Satodiya, Ritvij, Palekar, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546590/
https://www.ncbi.nlm.nih.gov/pubmed/33052290
http://dx.doi.org/10.7759/cureus.10329
_version_ 1783592249100075008
author Satodiya, Ritvij
Palekar, Nikhil
author_facet Satodiya, Ritvij
Palekar, Nikhil
author_sort Satodiya, Ritvij
collection PubMed
description Schizophrenia has a multidomain symptom cluster, including positive, negative, and cognitive symptoms. Synthetic cannabinoids (SC) commonly perpetuate the positive symptoms of schizophrenia. We present a case of predominant negative symptoms following the use of SC even though our patient had a consistent history of experiencing positive symptoms in the past. The hypoactive dopaminergic system in the prefrontal cortex can induce negative symptoms in schizophrenia. However, the modulating properties of SC on cannabinoid receptors can feed into the negative symptom progression. The psychoactive properties of SC need further research to understand its clinical characteristics.
format Online
Article
Text
id pubmed-7546590
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75465902020-10-12 Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia Satodiya, Ritvij Palekar, Nikhil Cureus Psychiatry Schizophrenia has a multidomain symptom cluster, including positive, negative, and cognitive symptoms. Synthetic cannabinoids (SC) commonly perpetuate the positive symptoms of schizophrenia. We present a case of predominant negative symptoms following the use of SC even though our patient had a consistent history of experiencing positive symptoms in the past. The hypoactive dopaminergic system in the prefrontal cortex can induce negative symptoms in schizophrenia. However, the modulating properties of SC on cannabinoid receptors can feed into the negative symptom progression. The psychoactive properties of SC need further research to understand its clinical characteristics. Cureus 2020-09-09 /pmc/articles/PMC7546590/ /pubmed/33052290 http://dx.doi.org/10.7759/cureus.10329 Text en Copyright © 2020, Satodiya et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Psychiatry
Satodiya, Ritvij
Palekar, Nikhil
Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title_full Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title_fullStr Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title_full_unstemmed Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title_short Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
title_sort synthetic cannabinoids and its association with persistent negative symptoms of schizophrenia
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546590/
https://www.ncbi.nlm.nih.gov/pubmed/33052290
http://dx.doi.org/10.7759/cureus.10329
work_keys_str_mv AT satodiyaritvij syntheticcannabinoidsanditsassociationwithpersistentnegativesymptomsofschizophrenia
AT palekarnikhil syntheticcannabinoidsanditsassociationwithpersistentnegativesymptomsofschizophrenia